Kintor Pharmaceutical Limited
HKSE: 9939.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Youzhi Tong
- Employees
- 168
- Headquarters
- Suzhou, China
- IPO year
- 2020
- Market cap
- HK$1.4B
- Website
- https://www.kintor.com.cn
Loading 9939…
Loading profile data…Frequently asked questions about 9939
What does Kintor Pharmaceutical Limited (9939.HK) do?
Kintor Pharmaceutical Limited, a clinical-stage biotechnology company, engages in developing and commercializing a pipeline of small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical needs in the People's Republic of China and internationally. The company's products pipeline include Proxalutamide...
Where does 9939.HK trade?
Kintor Pharmaceutical Limited (9939.HK) trades on the Hong Kong Stock Exchange.
What sector is 9939.HK in?
Kintor Pharmaceutical Limited (9939.HK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Kintor Pharmaceutical Limited?
Youzhi Tong is the chief executive officer of Kintor Pharmaceutical Limited (9939.HK).
Where is Kintor Pharmaceutical Limited headquartered?
Kintor Pharmaceutical Limited is headquartered in China.
Does 9939.HK pay a dividend?
Kintor Pharmaceutical Limited (9939.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 9939.HK go public?
Kintor Pharmaceutical Limited (9939.HK) completed its initial public offering in 2020.